AI Insight
Research has revealed that intravenous vitamin C, which achieves much higher blood concentrations than oral supplements, may have anticancer properties that differ fundamentally from nutritional supplementation. Unlike vitamin C pills, which showed no benefit in earlier trials, intravenous administration delivers doses high enough to potentially damage cancer cells directly. Early studies indicate it may reduce treatment side effects and possibly improve outcomes for certain patients, functioning more like an experimental drug than a traditional vitamin supplement.
Why it matters
This finding rehabilitates a previously dismissed therapeutic approach and could lead to new complementary cancer treatments. The research highlights the critical importance of delivery method in determining a substance's biological effects, potentially opening pathways for integrating high-dose intravenous vitamin C into conventional cancer care protocols.
Understand the Science
Linus Pauling was widely mocked for claiming that vitamin C could fight cancer, especially after trials using vitamin C pills showed no benefit. Researchers now know that intravenous vitamin C reaches vastly higher concentrations and can behave more like an experimental cancer drug than an ordinary supplement. Early studies suggest it may damage vulnerable cancer cells, reduce treatment side effects, and possibly improve outcomes for some patients.
Source: Vitamin C may fight cancer — but not the way scientists once thought